4basebio PLC (AIM:4BB)
London · Delayed Price · Currency is GBP · Price in GBX 525.00
0.00 (0.00%)
Jul 6, 2026, 8:00 AM GMT
4basebio Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, 4basebio stock has a consensus rating of "Buy" and an average price target of 1,600p. The average 1-year stock price forecast is 204.76% higher than the current stock price, while the lowest is 1,400p (+166.67%) and the highest is 1,800p (+242.86%).
Price Target: 1,600p (+204.76%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for 4basebio stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Feb '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains 1,400p | Buy | Maintains | 1,400p | +166.67% | Jun 16, 2026 |
Financial Forecast
Revenue This Year
2.80M
from 1.69M
Increased by 65.39%
Revenue Next Year
12.00M
from 2.80M
Increased by 328.57%
EPS This Year
-1.00
from -1.09
EPS Next Year
-0.60
from -1.00
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is GBP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3.0M | ||
| Avg | 2.8M | ||
| Low | 2.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 77.2% | ||
| Avg | 65.4% | ||
| Low | 53.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.00 | ||
| Avg | -1.00 | ||
| Low | -1.00 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |